Krka Talks Russia, Ukraine, One Year After Conflict Began
Slovenian Player Also Comments On Implications Of Ukrainian Legislation
Executive Summary
Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.
You may also be interested in...
Sandoz, Accord Confirm First US Aubagio Generics, As Settlement Day Arrives
Viatris’ Mylan and Teva are among firms holding approved ANDAs for generic Aubagio, as the product falls to generic competition in the US.
Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.
US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.